Retrospective Study
Copyright ©The Author(s) 2016.
World J Transplant. Jun 24, 2016; 6(2): 389-395
Published online Jun 24, 2016. doi: 10.5500/wjt.v6.i2.389
Table 1 Etiologic agents of ventilator-associated pneumonia
MicroorganismTotal (n = 18)
Klebsiella pneumonia5/18 (28%)
Escherichia coli5/18 (28%)
Klebsiella oxytoca2/18 (11%)
Enterobacter spp.1/18 (6%)
Citrobacter spp.1/18 (6%)
Pseudomonas aeruginosa8/18 (44%)
Staphylococcus aureus4/18 (22%)
Corynebacterium striatum4/18 (22%)
Xantomonas spp.2/18 (11%)
Acinetobacter spp.2/18 (11%)
Table 2 Preoperative, intraoperative and postoperative variables
VariablePatients in study (n = 242)VAP-yes (n = 18)VAP-no (n = 224)P-value
Age (yr)56 (19-69)55 (37-66)56 (19-69)0.624
Weight (kg)72 (39-106)73 (47-93)72 (39-106)0.515
Height (cm)170 (148-193)169 (155-182)170 (148-193)0.495
BMI (kg/m2)25 (16-38)24 (19-34)25 (16-38)0.452
BSA (m2)1.9 (1.3-2.3)1.9 (1.4-2.1)1.9 (1.3-2.3)0.505
HCV+128 (53%)8 (44%)120 (54%)0.455
HBV+49 (20%)3 (17%)46 (21%)0.486
Alcohol abuse37 (15%)3 (17%)34 (15%)0.540
HCC118 (49%)4 (22%)114 (51%)0.019
MELD score21 (6-48)23 (14-48)20 (6-45)0.032
CTP score11 (5-15)11 (9-14)11 (5-15)0.060
Bilirubin (mg/dL)5.9 (0.4-71.1)8.0 (2.1-71.1)5.6 (0.4-68.6)0.054
Creatinine (mg/dL)1.0 (0.0-5.2)1.1 (0.5-5.2)1.0 (0.0-4.9)0.708
INR1.6 (0.8-7.6)1.9 (1.3-3.8)1.6 (0.8-7.6)0.020
HbA1c (%)10.8 (4.5-17)9.9 (8.1-14.9)10.9 (4.5-17)0.085
Urea (mg/dL)0.3 (0.1-3.1)0.3 (0.1-2.6)0.3 (0.1-3.1)0.554
Serum glucose (mg/dL)105 (60-358)102 (63-284)105 (60-358)0.369
Albumin (g/dL)3.5 (2.0-5.3)3.3 (2.6-4.5)3.5 (2.0-5.3)0.189
TIPS presence15 (6%)1 (6%)14 (6%)0.691
Furosemide therapy144 (60%)11 (61%)133 (59%)0.885
Canrenoate therapy112 (46%)5 (28%)107 (48%)0.102
Terlipressin therapy20 (8.3%)7 (39%)13 (5.8%)< 0.001
Preoperative hospital stay82 (34%)11 (61%)71 (32%)0.018
Intraoperative and postoperative variables
Length of surgery (min)560 (512-650)570 (490-630)580 (460-660)0.067
Anhepatic phase duration (min)120 (88-138)118 (85-138)140 (116-145)0.067
RBC transfusions (units)8 (0-65)16 (6-48)7 (0-65)< 0.05
FFP transfusions (units)9 (0-75)10 (0-31)9 (0-35)0.122
Platelet transfusions (units)2 (0-4)2 (1-3)2 (1-3)0.587
CIT (h)7 (6-9)7 (7-9)8 (7-9)0.354
Pre-reperfusion VP infusion68 (28%)8 (22%)60 (26%)0.530
Post-reperfusion VP bolus110 (45%)8 (44%)102 (45%)0.520
Post-reperfusion VP infusion118 (48%)10 (55%)108 (48%)0.510
Duration of ICU stay (d)5 (3-10)16 (20-59)5 (3-8)< 0.05
Hospital mortality14 (6%)4 (22%)10 (4%)< 0.05
Median duration of MV (d)0.42 (0.208-0.417)1.125 (0.375-11.75)0.38 (0.208-0.864)< 0.05
Time between intubation and VAP insurgence (h)-72 (48-336)--
Table 3 Donor variables n (%)
VariablePatients in study (n = 242)VAP-yes (n = 18)VAP-no (n = 224)P-value
Donor age (yr)56 (14-89)58 (20-86)56 (19-80)0.624
Donor gender (male)182 (75)14 (77)168 (69)0.624
Donor risk index > 1.852 (21)4 (22)48 (21)0.345
Table 4 Variables associated with ventilator-associated pneumonia in multivariate analysis
VariableOR95%CIP-value
MELD score0.980.8-100.670
CTP score0.790.5-1.10.27
RBC transfusions (units)1.11.04-1.1< 0.001
MV (d)1.101.03-1.15< 0.001
Terlipressin therapy31.494.7-49.2< 0.001
Preoperative hospital stay (d)1.81-1.9< 0.05